Pipeline charts as communicated at (*) Q4 and Full Year 2019 Results R&D Pipeline – New Molecular Entities Meeting dated February 6, 2020 Phase 1 Phase 2 Phase 3 Registration (Total : 21) (Total : 7) (Total : 8) (Total : 2)

SAR441344(**)(1) ST400(**)(5) SAR440340(**)(11) SAR422459(**)(13) avalglucosidase alfa Sarclisa® Anti-CD40L mAb Ex Vivo ZFN Gene-Edited Cell Anti-IL33 mAb ABCA4 gene therapy Neo GAA Anti-CD38 mAb Multiple Sclerosis Therapy, Beta thalassemia Atopic Dermatitis Stargardt Disease Pompe Disease 3L RRMM (ICARIA) (U.S.,EU)

SAR439459 BIVV003(**)(5) romilkimab (SAR156597) SAR442168(**)(14) venglustat SAR341402 (insulin aspart) anti-TGFb mAb Ex Vivo ZFN Gene-Edited Cell Anti-IL4/IL13 bispecific mAb BTK inhibitor Oral GCS inhibitor Rapid acting insulin Advanced Solid Tumors Therapy, Sickle Cell Disease Systemic Scleroderma Multiple Sclerosis ADPKD(15) Type 1/2 Diabetes (EU)

REGN5458(**)(2) olipudase alfa SAR439859 fitusiran O BIVV020 R R Anti-BCMAxCD3 bispecific mAb rhASM SERD RNAi targeting anti-thrombin Complement C1s inhibitor Relapsed Refractory MM ASMD(12) ad+ped Metastatic 2/3L Hemophilia A and B

O REGN4018(**)(2) SAR443060(**)(6) SAR339375 Anti-MUC16xCD3 bispecific mAb RIPK1 inhibitor(7) miRNA-21 Anti Complement C1s mAb Ovarian Cancer Amyotrophic Lateral Sclerosis Alport Syndrome Cold Agglutinin Disease

SAR442720(**)(3) SAR443122(**)(6) BIVV001(**)(16) SHP2 inhibitor RIPK1 inhibitor(7) rFVIIIFc – vWF – XTEN(17) Solid Tumors Inflammatory indications Hemophilia A

SAR440234 SAR441169(**)(8) nirsevimab(**)(18) T cell engaging multi specific mAb RORC (ROR gamma T) antagonist, Respiratory syncytial virus Leukemia Psoriasis

SAR441000(**)(4) SAR441236 R Registrational Study (other than Phase 3) SAR408701 Cytokine mRNA Tri-specific neutralizing mAb Maytansin-loaded anti-CEACAM5 Solid tumors HIV O Opt-in rights products for which rights have not been exercised yet mAb, NSCLC 2/3L

SAR442085 Next Gen PCV(**)(9) Immuno-inflammation MS & Neuro efpeglenatide(19) Anti CD38 mAb Fc engineered Pneumococcal Conjugate Oncology Diabetes Long-acting GLP-1 agonist Vaccines Type 2 Diabetes Rare Diseases Cardiovascular & metabolism REGN5459(**)(2) O Herpes Simplex Virus Type 2(**)(10) Rare Blood Disorders Vaccines Anti-BCMAxCD3 bispecific mAb HSV-2 therapeutic vaccine Relapsed Refractory MM (1) Developed in collaboration with Immunext (14) Developed in collaboration with Principia (2) Regeneron product for which has opt-in rights (15) Autosomal Dominant Polycystic Kidney Disease THOR-707 Respiratory syncytial virus (3) Developed in collaboration with Revolution Medicines (16) Developed in collaboration with Sobi (4) Developed in collaboration with BioNTech Non-alpha IL-2 Infants 4-month and older (17) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein (5) Developed in collaboration with Sangamo (18) Developed in collaboration with AstraZeneca Solid tumors Vaccines (6) Developed in collaboration with Denali (19) Developed in collaboration with Hamni – Sanofi has committed to complete ongoing studies (7) Receptor-interacting serine/threonine-protein kinase 1 – Sanofi is looking for a partner to take over and commercialize efpeglenatide (8) Developed in collaboration with Lead Pharma (*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant Yellow Fever (9) Developed in collaboration with SK Vaccine (Vero cell) (**) Partnered and/or in collaboration – Sanofi may have limited or (10) Developed in collaboration with Immune Design/Merck shared rights on some of these products (11) Developed in collaboration with Regeneron mAb = monoclonal antibody; RRMM = Relapsed Refractory Multiple Myeloma;; (12) Acid Sphingomyelinase Deficiency also known as Niemann Pick type B GCS = glucosylceramide synthase 2 (13) Identification of out-licensing partner ongoing Pipeline charts as communicated at (*) Q4 and Full Year 2019 Results Additional Indications Meeting dated February 6, 2020 Phase 1 Phase 2 Phase 3 Registration (Total : 7) (Total : 17) (Total : 26) (Total : 3)

SAR439459 + (**)(1) (**)(1) + cemiplimab(**)(1) Dupixent®(**)(1) isatuximab Fluzone® QIV HD Advanced Solid Tumors Grass pollen allergy Relapsed Refractory MM Asthma 6 - 11 years old Newly Diag. MM Te(9) (GMMG) Influenza vaccine - High dose (EU)

O cemiplimab(**)(1) + REGN4018(**)(2) R (**)(1) isatuximab + cemiplimab(**)(1) dupilumab(**)(1) isatuximab MenQuadfiTM Ovarian Cancer Polyarticular Juvenile Idiopathic Arthritis Lymphoma Eosinophilic Esophagitis 2L RRMM (IKEMA) U.S. 2y+ , EU 1y+

SAR439859 + (3) R sarilumab(**)(1) isatuximab + (7) Dupixent®(**)(1) isatuximab Dupixent®(**)(1) Metastatic Breast Cancer Systemic Juvenile Arthritis mCRC AD 6 months - 5 years old 1L Newly Diag. MM Ti(10) (IMROZ) AD 6 – 11 years old (U.S., EU)

sutimlimab SAR440340(**)(1) isatuximab + atezolizumab(7) dupilumab(**)(1) Aubagio® Immune Thrombocytopenic Purpura COPD Solid Tumors COPD Relapsing MS – Pediatric

SAR443060(**)(4) dupilumab(**)(1) venglustat dupilumab(**)(1) Lemtrada® Multiple sclerosis Peanut Allergy - Pediatric Fabry Disease Bullous pemphigoid Relapsing Remitting MS - Pediatric

SAR442720(**)(5) + . SAR440340(**)(1) venglustat dupilumab(**)(1) Cerdelga® Relapsed Refractory solid tumors Asthma Gaucher Type 3 Chronic spontaneous urticaria Gaucher T1, ERT switch Pediatric

SAR441000(**)(6) + PD-1 R cemiplimab(**)(1) venglustat dupilumab(**)(1) Praluent® (**)(1) Solid tumors 2-L Basal Cell Carcinoma GBA-PD(8) Prurigo nodularis LDL-C reduction - Pediatric

isatuximab SP0173 sarilumab(**)(1) Praluent® (**)(1) 1-2L AML / ALL pediatrics Tdap booster US Giant Cell Arteritis LDL-C reduction – HoFH

SAR439859 sarilumab(**)(1) MenQuadfiTM Breast Cancer adjuvant Polymyalgia Rheumatica 6w+ (US / EU) R Registrational study (other than Phase 3) cemiplimab(**)(1) Pediatric pentavalent vaccine(**)(11) Immuno-inflammation O Opt-in rights products for which rights have not been exercised yet 1L NSCLC Japan Oncology

(1) Developed in collaboration with Regeneron (6) Developed in collaboration with BioNTech Rare Diseases cemiplimab(**)(1)+ chemotherapy Shan 6 (2) Regeneron product for which Sanofi has opt-in rights (7) Studies in collaboration with Inc. (atezolizumab) Rare Blood Disorders (3) Pfizer product (palbociclib) (8) Parkinson’s Disease with an associated GBA mutation 1L NSCLC Pediatric hexavalent vaccine (4) Developed in collaboration with Denali (9) Transplant eligible MS & Neuro (5) Developed in collaboration with Revolution Medicines - (10) Transplant ineligible cobimetinib is a Genentech product (11) Developed in collaboration with Kitasato and Daiichi Sankyo (KDSV) cemiplimab(**)(1) VerorabVax® (VRVg) Diabetes (*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant 2L Cervical Cancer Purified vero rabies vaccine (**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products Cardiovascular & metabolism COPD = chronic obstructive pulmonary disease; AML = acute myeloïd leukemia; ALL = acute lymphoblastic leukemia; Vaccines MM = multiple myloma;; RRMS = Relapsing / Remitting Multiple Sclerosis cemiplimab(**)(1) fitusiran adjuvant in CSCC Hemophilia A and B pediatric 3 Pipeline charts as communicated at Q4 and Full Year 2019 Results Pipeline movements since Q3 2019 Meeting dated February 6, 2020

Additions / Moves Removals from Sanofi pipeline

Dupixent®(**)(1 Registration AD 6 – 11 years old (U.S., EU)

BIVV001(**)(2) rFVIIIFc – vWF – XTEN(3) Hemophilia A

SAR408701 dupilumab(**)(1) Maytansin-loaded anti-CEACAM5 Phase 3 Chronic spontaneous urticaria mAb, NSCLC 2/3L

dupilumab(**)(1) dupilumab(**)(1) Bullous pemphigoid Prurigo nodularis

SAR439859 HIV SAR439859 SERD Viral vector prime & rgp120 boost Breast Cancer adjuvant Phase 2 Metastatic Breast Cancer 2./3L vaccine

SAR441000(**)(4) + PD-1 Yellow Fever Solid tumors Vaccine (Vero cell)

Phase 1 THOR-707 Non-alpha IL-2 Solid tumors

(1) Developed in collaboration with Regeneron (2) Developed in collaboration with Sobi (3) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein (4) Developed in collaboration with BioNTech (**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products 5